Table 3.

Drug-susceptible PTB treatment regimens

Each patient with diagnosis of drug-susceptible PTB should be treated with a regimen recommended by WHO and national guidelines Adults:  6-month regimen (2HRZE/4HR)  4-month regimen (2HPZMfx/2PMfx) for children aged >12 years and adults Children:  6-month regimen (2HRZ(E)*/4HR), with higher R and H dosing (see WHO-recommended dosages)  SHINE regimen (2HRZ(E)*/2HR) for age <16 years with non-severe TB†

^*E not always included, especially if susceptibility to R and H was confirmed.

^†Intrathoracic TB confined to opacification of <1 lobe with no cavities, no signs of military TB, no complex pleural effusion and no clinically significant airway obstruction; or only peripheral lymph node TB, drug-susceptible and smear-negative for acid-fast bacilli.

PTB = pulmonary TB; H = isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol; P = rifapentine; Mfx = moxifloxacin; SHINE = Shorter Treatment for Minimal Tuberculosis in Children